CD274 and colorectal carcinoma: These data, together with evidence that increased PD-L1 expression is associated with poor prognosis in stage III CRC,15 provide a compelling rationale for testing the efficacy of immune checkpoint inhibition in stage III dMMR/MSI-H CRC.